Abstract:We define previously unrecognized in vivo pathways of vitamin D-3 (D3) metabolism generating novel D3-hydroxyderivatives different from 25-hydroxyvitamin D-3 [25(OH)D3] and 1,25(OH)(2)D3. Their novel products include 20-hydroxyvitamin D-3 [20(OH) D3], 22(OH)D3, 20,23(OH)(2)D3, 20,22(OH)(2)D3, 1,20(OH)(2)D3, 1,20,23(OH)(3)D3, and 17,20,23(OH)(3)D3 and were produced by placenta, adrenal glands, and epidermal keratinocytes. We detected the predominant metabolite [20(OH)D3] in human serum with a relative concentration similar to 20 times lower than 25(OH)D3. Use of inhibitors and studies performed with isolated mitochondria and purified enzymes demonstrated involvement of the steroidogenic enzyme cytochrome P450scc (CYP11A1) as well as CYP27B1 (1 alpha-hydroxylase). In placenta and adrenal glands with high CYP11A1 expression, the predominant pathway was D3 -> 20(OH) D3 -> 20,23(OH)(2)D3 -> 17,20,23(OH)(3)D3 with further 1 alpha-hydroxylation, and minor pathways were D3 v 25(OH) D3 -> 1,25(OH)(2)D3 and D3 -> 22(OH) D3 -> 20,22(OH)(2)D3. In epidermal keratinocytes, we observed higher proportions of 22(OH)D3 and 20,22(OH)(2)D3. We also detected endogenous production of 20(OH)D3, 22(OH) D3, 20,23(OH)(2)D3, 20,22(OH)(2)D3, and 17,20,23(OH)(3)D3 by immortalized human keratinocytes. Thus, we provide in vivo evidence for novel pathways of D3 metabolism initiated by CYP11A1, with the product profile showing organ/cell type specificity and being modified by CYP27B1 activity. These findings define the pathway intermediates as natural products/endogenous bioregulators and break the current dogma that vitamin D is solely activated through the sequence D3 -> 25(OH)D3 -> 1,25(OH)(2)D3.-Slominski, A. T., Kim, T.-K., Shehabi, H. Z., Semak, I., Tang, E. K. Y., Nguyen, M. N., Benson, H. A. E., Korik, E., Janjetovic, Z., Chen, J., Yates, C. R., Postlethwaite, A., Li, W., Tuckey, R. C. In vivo evidence for a novel pathway of vitamin D3 metabolism initiated by P450scc and modified by CYP27B1. FASEB J. 26, 3901-3915 (2012). www.fasebj.org

Chemical synthesis, biological activities and action on nuclear receptors of 20S(OH)D3, 20S,25(OH)2D3, 20S,23S(OH)2D3 and 20S,23R(OH)2D3

Chemical Synthesis and Biological Activities of 20S,24s/r-Dihydroxyvitamin D3 Epimers and Their 1Α-Hydroxyl Derivatives

Design, synthesis, and biological activity of D-bishomo-1α,25-dihydroxyvitamin D 3 analogs and their crystal structures with the vitamin D nuclear receptor

Investigation of 20S-Hydroxyvitamin D3 Analogs and Their 1Α-Oh Derivatives As Potent Vitamin D Receptor Agonists with Anti-Inflammatory Activities

Synthesis and Biological Evaluation of Vitamin D3 Metabolite 20S,23s-Dihydroxyvitamin D3 and Its 23r Epimer

Total Synthesis of Biologically Active 20S-Hydroxyvitamin D3

4-Hydroxy-1α,25-Dihydroxyvitamin D3: Synthesis and Structure–Function Study

1Α,20s-Dihydroxyvitamin D3 Interacts with Vitamin D Receptor: Crystal Structure and Route of Chemical Synthesis

Synthesis and biological evaluation of 1α,25-dihydroxyvitamin D3 analogues with aromatic side chains attached at C-17.

Design, synthesis, and biological action of 20R-hydroxyvitamin D3.

Novel vitamin D analogs as potential therapeutics: metabolism, toxicity profiling, and antiproliferative activity.

[Biosynthesis of calcifediol and calcitriol: a review]

1α,25(OH)2-3-epi-vitamin D3, a natural physiological metabolite of vitamin D3: its synthesis, biological activity and crystal structure with its receptor

Production of 22-hydroxy metabolites of vitamin d3 by cytochrome p450scc (CYP11A1) and analysis of their biological activities on skin cells.

Synthesis of 1 Α, 25-Dihydroxyvitamin D3

In Vivo Evidence for A Novel Pathway of Vitamin D-3 Metabolism Initiated by P450scc and Modified by Cyp27b1

In vivo production of novel vitamin D2 hydroxy-derivatives by human placentas, epidermal keratinocytes, Caco-2 colon cells and the adrenal gland.

Design, Synthesis and Biological Activities of Novel Gemini 20S-Hydroxyvitamin D3 Analogs.

Synthesis and photo-conversion of androsta- and pregna-5,7-dienes to vitamin D3-like derivatives.

Novel Vitamin D3 Hydroxymetabolites Require Involvement of the Vitamin D Receptor or Retinoic Acid-Related Orphan Receptors for Their Antifibrogenic Activities in Human Fibroblasts

Metabolic activation of tachysterol3 to biologically active hydroxyderivatives that act on VDR, AhR, LXRs, and PPARγ receptors